Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Twelve Additional Countries

SAN DIEGO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
August 05, 2015 16:01 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Provides Corporate Update and Second Quarter 2015 Financial Results

RayVa™ Phase 2a Trial Top-Line Data Expected in Third Quarter Fispemifene Phase 2b Trial in Symptomatic Secondary Hypogonadism Enrolling on Schedule Recent Launches in Europe More than...
August 05, 2015 09:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to Present at the Canaccord Genuity 35th Annual Growth Conference

SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
July 30, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Corporate Update and Second Quarter 2015 Financial Results Conference Call

SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
June 15, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Last Patient Enrolled in RayVa(TM) Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma

Company Intends to Move Compound into Late Stage Development Top-line Data Expected in the Third Quarter of 2015 SAN DIEGO, June 15, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc....
June 01, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial for Fispemifene in Men With Symptomatic Secondary Hypogonadism

SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has...
May 28, 2015 16:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in France by Laboratoires Majorelle

SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch...
May 11, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Provides Corporate Update and First Quarter 2015 Financial Results

SAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial...
May 06, 2015 08:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Spain by Recordati

To Be Commercialized in Spain as Virirec(TM) Additional European Launches Expected Throughout 2015 SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a...
May 04, 2015 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Corporate Update and First Quarter 2015 Financial Results Conference Call

SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...